test

Phase II Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer

Conditions

Cancer

What is the purpose of this trial?

Primary Objective:
-To assess the incidence of grade 3 or higher drug related adverse event in the study population during the induction period of ipilimumab (Day 1 of treatment to Week 24).
Secondary Objective:
-To assess the best overall response rate (BORR) in the study population by mWHO, immune-related response criteria (irRC), and CA125 Rustin Criteria. [Rustin, GJ 1996; Gordon, JS 2003]


Participation Guidelines

Age:
18 Years and older
Gender:
Female

Click here for detailed information about who can participate in this trial.


Sponsor:
Bristol-Myers Squibb Company
Dates:
02/11/2013
Last Updated:
Study HIC#:
1207010549